Fibrocystic disease of the breast in premenopausal women

Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment

Joseph Monsonego, Marie Dominique Destable, Georges De Saint Florent, Jacques Amouroux, Jean Claude Kouyoumdjian, France Haour, Jean Luc Breau, Lucien Israel, Ana Maria Comaru-Schally, Andrew V Schally

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Sixty-six patients with fibrocystic mastopathy were enrolled in the trial after being selected according to clinical, radioultrasonographic, and histologic criteria. No characteristic hormonal profile was noted in most patients (52%). Estrogen receptors or progesterone receptors, or both, were found in 57% of patients. Hormone receptor levels were correlated with atypical proliferative mastopathy (87.5%). Mastopathy was associated with a uterine fibroma or a fibromatous uterus in 73% of cases. All patients received intramuscular injections of a sustained delivery system (microcapsules) of luteinizing hormone releasing hormone agonist [d-Trp6]-LHRH, Ipsen-Biotech, Paris) for 3 to 6 months. In case of partial response at 3 months, an antiestrogen (tamoxifen, 40 mg/day, for estrogen receptor-predominant lesions) or a progestin (cyproterone acetate, 50 mg/day, for progesterone receptor-predominant lesions) was added to the luteinizing hormone releasing hormone agonist. A complete response was observed in more than half of the patients (n = 35, 53%) treated by [d-Trp6]-LHRH alone (n = 29) or associated with tamoxifen (n = 4) or cyproterone acetate (n = 2). A significant partial response was observed in 30 other patients (45%). Additionally, half of them received inhibitory drugs. The best responses were seen with cyst reformation (complete response, 100%) and fibrous block. Clinical responses to treatment with [d-Trp6]-LHRH alone were independent of hormone receptor status, but synergistic effects occurred with concomitant use of the corresponding inhibitory drugs. We conclude that chronic mastopathy, particularly when associated with uterine fibroma, can be successfully treated by luteinizing hormone releasing hormone analogs in premenopausal women.

Original languageEnglish
Pages (from-to)1181-1189
Number of pages9
JournalAmerican Journal of Obstetrics and Gynecology
Volume164
Issue number5 PART 1
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Fibrocystic Breast Disease
Gonadotropin-Releasing Hormone
Cyproterone Acetate
Leiomyoma
Progesterone Receptors
Tamoxifen
Estrogen Receptors
Therapeutics
Hormones
Estrogen Receptor Modulators
Intramuscular Injections
Paris
Progestins
Pharmaceutical Preparations
Uterus
Capsules
Cysts

Keywords

  • estradiol receptors
  • luteinizing hormone releasing hormone analog
  • Proliferative mastopathy

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Fibrocystic disease of the breast in premenopausal women : Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. / Monsonego, Joseph; Destable, Marie Dominique; De Saint Florent, Georges; Amouroux, Jacques; Kouyoumdjian, Jean Claude; Haour, France; Breau, Jean Luc; Israel, Lucien; Comaru-Schally, Ana Maria; Schally, Andrew V.

In: American Journal of Obstetrics and Gynecology, Vol. 164, No. 5 PART 1, 01.01.1991, p. 1181-1189.

Research output: Contribution to journalArticle

Monsonego, J, Destable, MD, De Saint Florent, G, Amouroux, J, Kouyoumdjian, JC, Haour, F, Breau, JL, Israel, L, Comaru-Schally, AM & Schally, AV 1991, 'Fibrocystic disease of the breast in premenopausal women: Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment', American Journal of Obstetrics and Gynecology, vol. 164, no. 5 PART 1, pp. 1181-1189. https://doi.org/10.1016/0002-9378(91)90680-P
Monsonego, Joseph ; Destable, Marie Dominique ; De Saint Florent, Georges ; Amouroux, Jacques ; Kouyoumdjian, Jean Claude ; Haour, France ; Breau, Jean Luc ; Israel, Lucien ; Comaru-Schally, Ana Maria ; Schally, Andrew V. / Fibrocystic disease of the breast in premenopausal women : Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. In: American Journal of Obstetrics and Gynecology. 1991 ; Vol. 164, No. 5 PART 1. pp. 1181-1189.
@article{00aed1b26d7d42238ec724e78cc62a16,
title = "Fibrocystic disease of the breast in premenopausal women: Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment",
abstract = "Sixty-six patients with fibrocystic mastopathy were enrolled in the trial after being selected according to clinical, radioultrasonographic, and histologic criteria. No characteristic hormonal profile was noted in most patients (52{\%}). Estrogen receptors or progesterone receptors, or both, were found in 57{\%} of patients. Hormone receptor levels were correlated with atypical proliferative mastopathy (87.5{\%}). Mastopathy was associated with a uterine fibroma or a fibromatous uterus in 73{\%} of cases. All patients received intramuscular injections of a sustained delivery system (microcapsules) of luteinizing hormone releasing hormone agonist [d-Trp6]-LHRH, Ipsen-Biotech, Paris) for 3 to 6 months. In case of partial response at 3 months, an antiestrogen (tamoxifen, 40 mg/day, for estrogen receptor-predominant lesions) or a progestin (cyproterone acetate, 50 mg/day, for progesterone receptor-predominant lesions) was added to the luteinizing hormone releasing hormone agonist. A complete response was observed in more than half of the patients (n = 35, 53{\%}) treated by [d-Trp6]-LHRH alone (n = 29) or associated with tamoxifen (n = 4) or cyproterone acetate (n = 2). A significant partial response was observed in 30 other patients (45{\%}). Additionally, half of them received inhibitory drugs. The best responses were seen with cyst reformation (complete response, 100{\%}) and fibrous block. Clinical responses to treatment with [d-Trp6]-LHRH alone were independent of hormone receptor status, but synergistic effects occurred with concomitant use of the corresponding inhibitory drugs. We conclude that chronic mastopathy, particularly when associated with uterine fibroma, can be successfully treated by luteinizing hormone releasing hormone analogs in premenopausal women.",
keywords = "estradiol receptors, luteinizing hormone releasing hormone analog, Proliferative mastopathy",
author = "Joseph Monsonego and Destable, {Marie Dominique} and {De Saint Florent}, Georges and Jacques Amouroux and Kouyoumdjian, {Jean Claude} and France Haour and Breau, {Jean Luc} and Lucien Israel and Comaru-Schally, {Ana Maria} and Schally, {Andrew V}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0002-9378(91)90680-P",
language = "English",
volume = "164",
pages = "1181--1189",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5 PART 1",

}

TY - JOUR

T1 - Fibrocystic disease of the breast in premenopausal women

T2 - Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment

AU - Monsonego, Joseph

AU - Destable, Marie Dominique

AU - De Saint Florent, Georges

AU - Amouroux, Jacques

AU - Kouyoumdjian, Jean Claude

AU - Haour, France

AU - Breau, Jean Luc

AU - Israel, Lucien

AU - Comaru-Schally, Ana Maria

AU - Schally, Andrew V

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Sixty-six patients with fibrocystic mastopathy were enrolled in the trial after being selected according to clinical, radioultrasonographic, and histologic criteria. No characteristic hormonal profile was noted in most patients (52%). Estrogen receptors or progesterone receptors, or both, were found in 57% of patients. Hormone receptor levels were correlated with atypical proliferative mastopathy (87.5%). Mastopathy was associated with a uterine fibroma or a fibromatous uterus in 73% of cases. All patients received intramuscular injections of a sustained delivery system (microcapsules) of luteinizing hormone releasing hormone agonist [d-Trp6]-LHRH, Ipsen-Biotech, Paris) for 3 to 6 months. In case of partial response at 3 months, an antiestrogen (tamoxifen, 40 mg/day, for estrogen receptor-predominant lesions) or a progestin (cyproterone acetate, 50 mg/day, for progesterone receptor-predominant lesions) was added to the luteinizing hormone releasing hormone agonist. A complete response was observed in more than half of the patients (n = 35, 53%) treated by [d-Trp6]-LHRH alone (n = 29) or associated with tamoxifen (n = 4) or cyproterone acetate (n = 2). A significant partial response was observed in 30 other patients (45%). Additionally, half of them received inhibitory drugs. The best responses were seen with cyst reformation (complete response, 100%) and fibrous block. Clinical responses to treatment with [d-Trp6]-LHRH alone were independent of hormone receptor status, but synergistic effects occurred with concomitant use of the corresponding inhibitory drugs. We conclude that chronic mastopathy, particularly when associated with uterine fibroma, can be successfully treated by luteinizing hormone releasing hormone analogs in premenopausal women.

AB - Sixty-six patients with fibrocystic mastopathy were enrolled in the trial after being selected according to clinical, radioultrasonographic, and histologic criteria. No characteristic hormonal profile was noted in most patients (52%). Estrogen receptors or progesterone receptors, or both, were found in 57% of patients. Hormone receptor levels were correlated with atypical proliferative mastopathy (87.5%). Mastopathy was associated with a uterine fibroma or a fibromatous uterus in 73% of cases. All patients received intramuscular injections of a sustained delivery system (microcapsules) of luteinizing hormone releasing hormone agonist [d-Trp6]-LHRH, Ipsen-Biotech, Paris) for 3 to 6 months. In case of partial response at 3 months, an antiestrogen (tamoxifen, 40 mg/day, for estrogen receptor-predominant lesions) or a progestin (cyproterone acetate, 50 mg/day, for progesterone receptor-predominant lesions) was added to the luteinizing hormone releasing hormone agonist. A complete response was observed in more than half of the patients (n = 35, 53%) treated by [d-Trp6]-LHRH alone (n = 29) or associated with tamoxifen (n = 4) or cyproterone acetate (n = 2). A significant partial response was observed in 30 other patients (45%). Additionally, half of them received inhibitory drugs. The best responses were seen with cyst reformation (complete response, 100%) and fibrous block. Clinical responses to treatment with [d-Trp6]-LHRH alone were independent of hormone receptor status, but synergistic effects occurred with concomitant use of the corresponding inhibitory drugs. We conclude that chronic mastopathy, particularly when associated with uterine fibroma, can be successfully treated by luteinizing hormone releasing hormone analogs in premenopausal women.

KW - estradiol receptors

KW - luteinizing hormone releasing hormone analog

KW - Proliferative mastopathy

UR - http://www.scopus.com/inward/record.url?scp=0025774568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025774568&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(91)90680-P

DO - 10.1016/0002-9378(91)90680-P

M3 - Article

VL - 164

SP - 1181

EP - 1189

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 5 PART 1

ER -